Statins increase rifampin Mycobactericidal effect

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5766-5774

  Lobato, Lívia Silva ^a   Rosa, Patricia Sammarco ^b   Da Silva Ferreira, Jessica ^a   Da Silva Neumann, Arthur ^a   Da Silva, Marlei Gomes ^c   Nascimento, Dejair Caitano ^b   Soares, Cleverson Teixeira ^b   Pedrini, Silvia Cristina Barbosa ^b   De Oliveira, Diego Sá Leal ^a   Monteiro, Cláudia Peres ^b   Pereira, Geraldo Moura Batista ^a   Ribeiro Alves, Marcelo ^d   Hacker, Mariana Andrea ^a   Moraes, Milton Ozório ^a   Pessolani, Maria Cristina Vidal ^a   Duarte, Rafael Silva ^c   Lara, Flávio Alves ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto Lauro de Sousa Lima   (Brazil)

^c Cidade Universitária   (Brazil)

^d Funda??o Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BACTERIAL DNA; CHOLESTEROL; MESSENGER RNA; RIFAMPICIN; RNA 16S; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; FOOT PAD; HUMAN; HUMAN CELL; INCUBATION TIME; INFLAMMATORY INFILTRATE; LEPROSY; MACROPHAGE; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DRUG EFFECTS; DRUG POTENTIATION; MICROBIOLOGY; PATHOGENICITY;

ANIMALS; ANTITUBERCULAR AGENTS; ATORVASTATIN CALCIUM; CELL LINE; DRUG SYNERGISM; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEPROSY; MACROPHAGES; MICE; MICE, INBRED BALB C; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; PYRROLES; RIFAMPIN; SIMVASTATIN;

EID: 84907266304     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01826-13     Document Type: Article

References (45)

1. WHO. 2012. Global tuberculosis report 2012. World Health Organiza tion, Geneva, Switzerland, http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf.
2. WHO. 2012. Global leprosy situation, 2012. Wkly. Epidemiol. Rec. 87: 317-328.
3. Williams DL, Gillis TP. 2012. Drug-resistant leprosy: monitoring and current status. Lepr. Rev. 83:269-281.
4. WHO. 2011. Surveillance of drug resistance in leprosy: 2010. Wkly. Epidemiol. Rec. 86:237-240.
5. Mattos KA, Lara FA, Oliveira VG, Rodrigues LS, DAvila H, Melo RC, Manso PP, Sarno EN, Bozza PT, Pessolani MC. 2011. Modulation of lipid droplets by Mycobacterium leprae in Schwann cells: a putative mechanism for host lipid acquisition and bacterial survival in phagosomes. Cell. Mi-crobiol.13:259-273. http//dx.doi.org/10.1111/j.1462-5822.2010.01533.x.
6. Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, Visser A, Wang W, Hsu FF, Wiehart U, Tsenova L, Kaplan G, Russell DG. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol. Med. 2:258-274. http://dx.doi.org/10.1002/emmm.201000079.
7. Mattos KA, DAvila H, Rodrigues LS, Oliveira VG, Sarno EN, Atella GC, Pereira GM, Bozza PT, Pessolani MC. 2010. Lipid droplet formation in leprosy: Toll-like receptor-regulated organelles involved in eicosanoid formation and Mycobacterium leprae pathogenesis. J. Leukoc. Biol. 87:371-384. http://dx.doi.org/10.1189/jlb.0609433.
8. Parihar SP, Guler R, Khutlang R, Lang DM, Hurdayal R, Mhlanga MM, Suzuki H, Marais AD, Brombacher F. 2013. Statin therapy reduces Mycobacterium tuberculosis infection in human macrophages and in mice by enhancing autophagy and phagosome maturation. J. Infect. Dis. 209: 754-763. http://dx.doi.org/10.1093/infdis/jit550.
9. Pohl PC, Klafke GM, Junior JR, Martins JR, da Silva Vaz I, Jr, Masuda A. 2012. ABC transporters as a multidrug detoxification mechanism in Rhipicephalus (Boophilus) microplus. Parasitol. Res. 111:2345-2351. http: //dx.doi.org/10.1007/s00436-012-3089-1.
10. Al-Mubarak R, Vander Heiden J, Broeckling CD, Balagon M, Brennan PJ, Vissa VD. 2011. Serum metabolomics reveals higher levels of polyunsaturated fatty acids in lepromatous leprosy: potential markers for susceptibility and pathogenesis. PLoS Negl. Trop. Dis. 5:e1303. http://dx.doi.org/10.1371/journal.pntd.0001303.
11. Mattos KA, Oliveira VC, Berrêdo-Pinho M, Amaral JJ, Antunes LC, Melo RC, Acosta CC, Moura DF, Olmo R, Han J, Rosa PS, Almeida PE, Finlay BB, Borchers CH, Sarno EN, Bozza PT, Atella GC, Pessolani MC. 2014. Mycobacterium leprae intracellular survival relies on cholesterol accumulation in infected macrophages: a potential target for new drugs for leprosy treatment. Cell. Microbiol. 16:797-815. http://dx.doi.org/10.1111/cmi.12279.
12. Tanigawa K, Degang Y, Kawashima A, Akama T, Yoshihara A, Ishido Y, Makino M, Ishii N, Suzuki K. 2012. Essential role of hormone-sensitive lipase (HSL) in the maintenance of lipid storage in Mycobacterium lepraeinfected macrophages. Microb. Pathog. 52:285-291. http://dx.doi.org/10.1016/j.micpath.2012.02.003.
13. Marques MA, Neves-Ferreira AG, da Silveira EK, Valente RH, Chapeaurouge A, Perales J, da Silva Bernardes R, Dobos KM, Spencer JS, Brennan PJ, Pessolani MC. 2008. Deciphering the proteomic profile of Mycobacterium leprae cell envelope. Proteomics 8:2477-2491. http://dx.doi.org/10.1002/pmic.200700971.
14. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honoré N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG. 2001. Massive gene decay in the leprosy bacillus. Nature 409: 1007-1011. http://dx.doi.org/10.1038/35059006.
15. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, III, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544. http://dx.doi.org/10.1038/31159.
16. Cruz D, Watson AD, Miller CS, Montoya D, Ochoa MT, Sieling PA, Gutierrez MA, Navab M, Reddy ST, Witztum JL, Fogelman AM, Rea TH, Eisenberg D, Berliner J, Modlin RL. 2008. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J. Clin. Invest. 118:2917-2928. http://dx.doi.org/10.1172/JCI34189.
17. Brzostek A, Pawelczyk J, Rumijowska-Galewicz A, Dziadek B, Dziadek J. 2009. Mycobacterium tuberculosis is able to accumulate and utilize cholesterol. J. Bacteriol. 191:6584-6591. http://dx.doi.org/10.1128/JB.00488-09.
18. de Chastellier C, Thilo L. 2006. Cholesterol depletion in Mycobacterium avium-infected macrophages overcomes the block in phagosome maturation and leads to the reversible sequestration of viable mycobacteria in phagolysosome-derived autophagic vacuoles. Cell. Microbiol. 8:242-256. http://dx.doi.org/10.1111/j.1462-5822.2005.00617.x.
19. Pandey AK, Sassetti CM. 2008. Mycobacterial persistence requires the utilization of host cholesterol. Proc. Natl. Acad. Sci. U. S. A. 105:43764380. http://dx.doi.org/10.1073/pnas.0711159105.
20. Yamashita M, Otsuka F, Mukai T, Otani H, Inagaki K, Miyoshi T, Goto J, Yamamura M, Makino H. 2008. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rhomitogen-activated protein kinase pathway. J. Endocrinol. 196:601-613. http://dx.doi.org/10.1677/JOE-07-0532.
21. Pedersen TR. 2010. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Am. J. Cardiovasc. Drugs 10(Suppl 1): S10-S17. http://dx.doi.org/10.2165/1158822-S0-000000000-00000.
22. Pharmazie in unserer Zeit. 2003. High therapeutic effect and safety of fluvastatin. Pharm. Unserer Zeit 32:516-517. (In German.) http://dx.doi.org/10.1002/pauz.200390134.
23. Martinez AN, Lahiri R, Pittman TL, Scollard D, Truman R, Moraes MO, Williams DL. 2009. Molecular determination of Mycobacterium leprae viability by use of real-time PCR. J. Clin. Microbiol. 47:2124-2130. http://dx.doi.org/10.1128/JCM.00512-09.
24. Lahiri R, Randhawa B, Krahenbuhl JL. 2005. Effects of purification and fluorescent staining on viability of Mycobacterium leprae. Int. J. Lepr. Other Mycobact. Dis. 73:194-202.
25. Seto S, Matsumoto S, Ohta I, Tsujimura K, Koide Y. 2009. Dissection of Rab7 localization on Mycobacterium tuberculosis phagosome. Biochem. Biophys. Res. Commun. 387:272-277. http://dx.doi.org/10.1016/j.bbrc.2009.06.152.
26. Ribeiro-Resende VT, Ribeiro-Guimaräes ML, Lemes RM, Nascimento IC, Alves L, Mendez-Otero R, Pessolani MC, Lara FA. 2010. Involvement of 9-O-acetyl GD3 ganglioside in Mycobacterium leprae infection of Schwann cells. J. Biol. Chem. 285:34086-34096. http://dx.doi.org/10.1074/jbc.M110.147272.
27. de Jonge MI, Pehau -Arnaudet G, Fretz MM, Romain F, Bottai D, Brodin P, Honoré N, Marchai G, Jiskoot W, England P, Cole ST, Brosch R. 2007. ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J. Bacteriol. 189:6028-6034. http://dx.doi.org/10.1128/JB.00469-07.
28. Mattos KA, Oliveira VG, DAvila H, Rodrigues LS, Pinheiro RO, Sarno EN, Pessolani MC, Bozza PT. 2011. TLR6-driven lipid droplets in Mycobacterium leprae-infected Schwann cells: immunoinflammatory platforms associated with bacterial persistence. J. Immunol. 187:2548-2558. http://dx.doi.org/10.4049/jimmunol.1101344.
29. Ahmad Z, Sharma S, Khuller GK. 2005. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 26:298-303. http://dx.doi.0rg/10.1016/j.ijantimicag.2005.07.012.
30. Hu Y, Van Der Geize R, Besra GS, Gurcha SS, Liu A, Rohde M, Singh M, Coates A. 2010. 3-Ketosteroid 9a-hydroxylase is an essential factor in the pathogenesis of Mycobacterium tuberculosis. Mol. Microbiol. 75:107121. http://dx.doi.org/10.1111/j.1365-2958.2009.06957.x.
31. Nesbitt NM, Yang X, Fontán P, Kolesnikova I, Smith I, Sampson NS, Dubnau E. 2010. A thiolase of Mycobacterium tuberculosis is required for virulence and production of androstenedione and androstadienedione from cholesterol. Infect. Immun. 78:275-282. http://dx.doi.org/10.1128/IAI.00893-09.
32. Klink M, Brzezinska M, Szulc I, Brzostek A, Kielbik M, Sulowska Z, Dziadek J. 2013. Cholesterol oxidase is indispensable in the pathogenesis of Mycobacterium tuberculosis. PLoS One 8:e73333. http://dx.doi.org/10.1371/journal.pone.0073333.
33. Brzezinska M, Szulc I, Brzostek A, Klink M, Kielbik M, Sulowska Z, Pawelczyk J, Dziadek J. 2013. The role of 3-ketosteroid 1(2)-dehydrogenase in the pathogenicity of Mycobacterium tuberculosis. BMC Microbiol. 13:43. http://dx.doi.org/10.1186/1471-2180-13-43.
34. Abdoli N, Heidari R, Azarmi Y, Eghbal MA. 2013. Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes. J. Biochem. Mol. Toxicol. 27:287-294. http://dx.doi.org/10.1002/jbt.21485.
35. Lu HZ, Li BQ. 2009. Effect of HMG-CoA reductase inhibitors on activation of human gammadeltaT cells induced by Mycobacterium tuberculosis antigens. Immunopharmacol. Immunotoxicol. 31:485-491. http://dx.doi.org/10.1080/08923970902806505.
36. Reagan-Shaw S, Nihal M, Ahmad N. 2008. Dose translation from animal to human studies revisited. FASEB J. 22:659-661. http://dx.doi.org/10.1096/fj,07-9574LSF.
37. Benati D, Ferro M, Savino MT, Ulivieri C, Schiavo E, Nuccitelli A, Pasini FL, Baldari CT. 2010. Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus. J. Leukoc. Biol. 87:433-442. http://dx.doi.org/10.1189/jlb.0409273.
38. Wu B.Q. , Luo J.M., Wang Y.H., Shi Y.F., Liu H., Ba J.H., Zhang T.T.. 2013.3Inhibitory effects of simvastatin on Staphylococcus aureus lipoteichoic acid-3induced inflammation in human alveolar macrophages. Clin. Exp.3Med. 14:151-160.
39. Zhang S, Rahman M, Zhang S, Qi Z, Thorlacius H. 2011. Simvastatin antagonizes CD40L secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in abdominal sepsis. J. Leukoc. Biol. 89: 735-742. http://dx.doi.org/10.1189/jlb.0510279.
40. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. 2004. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608. http://dx .doi.org/10.1016/S0140-6736(04)16205-3.
41. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. 2002. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J. Cell Sci. 115: 2603-2611.
42. Greenwood J, Steinman L, Zamvil SS. 2006. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6:358-370. http://dx.doi.org/10.1038/nri1839.
43. Ghittoni R, Patrussi L, Pirozzi K, Pellegrini M, Lazzerini PE, Capecchi PL, Pasini FL, Baldari CT. 2005. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 19:605-607. http://dx.doi.org/10.1096/fj.04-2702fje.
44. Ghittoni R, Napolitani G, Benati D, Ulivieri C, Patrussi L, Laghi Pasini F, Lanzavecchia A, Baldari CT. 2006. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur. J. Immunol. 36:2885-2893. http://dx.doi.org/10 .1002/eji.200636567.
45. Sarno EN, Grau GE, Vieira LM, Nery JA. 1991. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin. Exp. Immunol. 84:103-108.